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Objective: To study cross-reactions to Echinococcus granulosus hydatid fluid antigen (EgHF) in  ELISA tests on serum 
from patients with malignancies. 
Methods: The study was based on the use of different ELlSAs and a subsequent Western blot test for the confirmation 
of positive ELISA results. 
Results: We found that cross-reactions with the EgHF ELISA were unusually high (6.3%) in patients with malignancies 
as compared with sera from healthy subjects (0.5%. p<0.05). Seropositive patients suffered significantly less frequently 
from advanced, consuming malignancy as compared with patients with a negative EgHF ELISA (24% versus 55%, 
p<0.05). The Western blot test remained negative with respect t o  the diagnostically relevant 8-kDa band in all patients 
with a positive EgHF ELSA reaction. 
Conclusions: The screening EgHF ELISA for E. granulosus is associated with relatively frequent false-positive 
reactions in  tumor patients, whereas the Western blot test is a specific immunodiagnostic tool enabling discrimination 
between malignancy and parasitic hydatid disease. 
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INTRODUCTION 
Hydatid diseases 
The two major parasite species related to hydatid 
disease are Ecliiizococcirr gruritrlosus, causing cystic hydatid 
disease, and E. mtrltiloculuris, causing alveolar hydatid 
disease, also known as alveolar echinococcosis [ 1 4 .  
Both parasites are intestinal tapeworms, primarily of 
dogs and foxes, respectively. Humans become inter- 
mediate hosts when they accidentally ingest parasite 
eggs passed in the feces of infected definitive hosts [ 1 4 .  
For E. g~urzulosus, the majority of primary infections in 
humans result in the formation of single cysts. In over 
65% of cases, the liver is the primary site of hydatid cyst 
localization, followed by the lungs (25%), spleen, 
kidneys, heart, bone, and, rarely, the central nervous 
system (1-36) [ 1,3]. Parasite lesions related to alveolar 
hydatid disease are localized in the liver in more than 
99% of cases. Metastatic lesions to retroperitoneal sites, 
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the lungs, brain and other organs can follow [l]. 
Surgery as the primary tool of treatment is frequently 
complemented by chemotherapy with benziniidazole 
compounds [4]. 
lmmunodiagnosis of hydatid diseases 
Older tests such as the complement-fixation test, 
indirect hemagglutination test (IHA), Casoni's intra- 
dermal test, indirect immunofluorescent test (IFAT) 
and latex agglutination test (LAT) have been replaced 
today by more modern immunodiagnostic tools. These 
include sensitive screening tests such as ELISA, 
followed by rather specific confirmation tests such as 
arc-5 iinmunoelectrophoresis (IEP) or counter- 
immunoelectrophoresis (CIE) tests, Western blotting or 
similar procedures [5-71. 
The diagnostic sensitivity of ELISA tests varies 
from 60% to 90% for E. grunulorur, depending on the 
characteristics of the cases, and from 94% to 98%) for E. 
~zulfiloctrluvir [6]. Thus, problems related to diagnostic 
sensitivity appear to be less important in serodiagnosis 
of E. ~ ~ ~ f i l o r ~ 4 ~ u ~ i s .  However, false-positive reactions 
with serum antibodies from persons with another 
parasitic disease or non-parasitic hepatic disease are well 
known [5,7,8]. Some false-positive reactions in cancer 
patients have been reported with regard to serologic 
tests such as IHA and CIE [9-121. For ELISA, to the 
best of our knowledge insufficient data are available 
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concerning cross-reactions with serum from patients 
with malignancies. 
Objectives of the study 
The objective of this study was to assess the frequency 
and underlying disease of positive reactions in different 
serologic Echinococcur tests with serum from patients 
suffering from different malignancies and not infected 
with E. granulosus. The serologic approach was based 
upon different ELISAs and a Western blot test, used for 
the confirmation of positive ELISA results. 
PATIENTS AND METHODS 
Patients 
Two hundred and seventy patients (133 maled137 
females; mean (SD) age 57.5213.5 years) admitted to 
the outpatient clinic of the institute of Oncology, 
University Hospital of Berne, were enrolled in the 
study from March 1995 to March 1997. Inclusion 
criteria were: histologically confirmed malignancy, no 
history or radiologic finding suggestive of hydatid 
disease, and age between 18 and 85 years. 
Methods 
The primary serologic analysis of the patient’s serum 
was performed with an E. granulosus screening EgHF 
ELISA using hydatid fluid antigen of bovine origin [5] 
and two different E. rnultilocrrtaris ELISAs including 
the Em3 ELISA and the recombinant 11/3-10 ELISA 
[5,13]. The threshold criteria discriminating between 
‘seronegativity’ and ‘seropositivity’ were for, all ELISAs, 
exactly as described previously [5]. SDS-PAGE and 
Western blot for the detection of antibody reactivity 
against the smallest 8 kDa subunit of antigen B was 
performed exactly as described by Maddison et al [14]. 
Statistical criteria used to determine cut-off threshold 
values were as described previously [5]. 
Statistics 
The statistics software package SYSTAT was used for 
data analysis (SYSTAT 6.01, SSPS Inc., Chcago, IL, 
USA). Data are expressed as mean values ? standard 
deviation (SD). Fisher’s exact test and regression 
analysis were applied as appropriate. 
RESULTS 
ELISA test results 
In 17 (6.3%) of 270 patients examined, a positive EgHF 
ELISA reaction was detected (median antibody concen- 
tration 8.0 AU (antibody units): range 1.0-33.0 AU) 
(Figure 1). Two of these 17 patients also showed a 
slightly positive Em2 ELSA reaction: 2 and 10 AU, 
respectively. The recombinant 11/3-10 ELISA was 
negative in all 270 patients. The mean age of the 
patients with a positive ELISA reaction was 59.023.3 
years (7 femaledl0 females) versus 57.420.9 years (130 
femaledl23 males) in patients with a negative ELISA 
reaction. 
Type of neoplasm 
The distributions of the different malignancies were 
similar in both patient groups. Gastrointestinal neo- 
plasms (6/17 (35%) in patients with a positive EgHF 
ELISA versus 41/253 (16%) in patients with a negative 
EgHF ELISA, p=0.09) and lymphoma (2/17 (12%) 
versus 66/253 (36%), p=0.25) were the most fiequent 
malignancies, followed by breast cancer and lung 
cancer. Patients with a positive EgHF ELISA reaction 
exhibited extensive disease, including metastasis, less 
frequently than patients with a negative EgHF ELISA 
reaction (Table 1). 
No statistical correlation between the EgHF 
ELISA results with regard to the individual antibody 
concentration (AU) and either the extension of the 
neoplasm or the stage of cancer could be found. 
Furthermore, the difference with respect to the treat- 
ment of malignancies, including combined radio- 
therapy and chemotherapy, was not significant when 
comparing the two patient groups. 
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Figure 1 Positive E. granulosus screening EgHF ELISA 
reaction for E. grunulosus in patients with malignancy and 
no E. granulosus infection (n=17). AU denotes EgHF 
ELISA antibody concentration in antibody units. 
Seropositivity is provided by AU values 21 AU (negative 
values are expressed as 0 AU) (51. For comparative purposes, 
it may be noted that 91% of E. granulosus hydatid disease 
patients exhibited seropositive reactions in EgHF ELISA 
with ranges between 5 and 112 AU (medan 65 AU) [15]. 
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Table 1 The different cancer treatments in patients with a 
positive E. gvanulorus hydatid fluid antigen EgHF ELISA 
(n  =17) versus seronegative patients (n 4 5 3 )  
Resection of f, M e t r i s  
Patients with Patients with 
negative EgHF positive EgHF 
ELISA reaction ELISA reaction 
n % n ?h 
~ ~~ 
Neoplasm in remission 48 26 8 47 
Linuted neoplasma 67 19 5 29 
Extensive neoplasmh 138 55 4 24 
'Tumor with no metastasis or local infdtration; "tumor with 
metastasis and/or local infdtration; 'pi0.05 (Fisher's exact test) 
Follow-up in a patient with a nasopharyngeal cancer 
In order to study the kinetics of antibody reactivity in 
the time course of an EgHF ELISA-seropositive 
patient, we studied a male 65-year-old patient with a 
nasopharyngeal neoplasm with four ELISA determina- 
tions a t  different times. After chemotherapy and 
radiotherapy of the cancer, a significant decrease in the 
EgHF ELISA antibody concentration was observed 
within a period of 4 months. Subsequent to this 
decrease, no further significant alteration in the anti- 
body concentration occurred. The concentration 
remained constant and close to the threshold level, even 
after an interval of more than 18 months (Figure 2). 
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Figure 2 Time course of the EgHF ELISA antibody 
concentration in a seropositive patient (male, age 65 years) 
with a metastatic nasopharyngeal neoplasm type 
Schmincke-Regaud after chemo- and radiotherapy as well 
as surgery of an intrapulmonary metastasis. AU denotes 
EgHF ELISA antibody concentration in antibody units. 
Seropositivity is provided by AU values 21 AU (negative 
values are expressed as 0 AU) [5]. 
Control of the sera with a positive ELISA reaction with 
the Western blot test 
In all sera of the 17 patients with a positive EgHF 
ELISA reaction, the Western blot test remained 
negative with respect to the diagnostically relevant 
8-kDa band [14]. With regard to the global banding 
pattern, including non-specific bands of other niole- 
cular size, 13 of the 17 patients in question had no 
single band reactivity and were thus completely negative 
in Western blots. Two patients exhibited a single band 
reactivity with a 13-kDa band, and two other patients 
with a 27-kDa band. 
DISCUSSION 
In sera from patients with different malignancies and 
not infected with E. gvanulosus, the frequency of cross- 
reactions with the E. granulosus screening EgHF ELISA 
(hydatid fluid antigen) is higher as compared with 
previously published data from healthy subjects using 
the same assay performed in the same laboratory (6.3% 
versus 0.5%, y<0.05) [ 5 ] .  O n  the other hand, only two 
tumor patients with positive EgHF ELISA reaction 
showed a slightly positive Em2 ELISA reaction, and the 
recombinant 11/3-10 ELISA was negative in all studied 
patients. False-positive EgHF ELISA reactions are well 
known to occur with the serum of persons harboring 
other parasitic infections, but also with liver cirrhosis, 
non-parasitic cysts and conditions of altered immunity 
[5,6,8]. In a patient group with other parasitic infections 
or non-parasitic hepatic disease, more cross-reactions 
were observed with the widely used hydatid fluid 
antigen (specificity=61%) as compared with the Em2 
antigen (specificity= 100%) or  with the recombinant 
11/3-10 antigen (specificity=98%). In contrast to our 
findings in patients with malignancy, the cross-reactions 
of the two latter tests in patients with other parasitic 
infections or non-parasitic hepatic disease were of low 
intensity (ranging between 1 and 6 AU) and were thus 
only slightly above the negative-positive cut-off point 
Seropositive tumor patients had no evidence of 
relevant hepatic disease, with the exception of two 
patients with liver metastasis. Tumor patients with a 
positive EgHF reaction had no clinical or other 
laboratory evidence of a parasitic infection, although 
we still cannot absolutely rule out an occult parasitic 
infection. 
Remarkably, the Western blot test remained 
negative with respect to the diagnostically relevant 
8-kDa band in all tumor patients with a positive E. 
granulosus screening EgHF ELISA reaction. These 
findings correspond to the report of Maddison et a1 
[14], describing a specificity of 100% for 205 patients 
PI. 
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with other parasitic infections or non-parasitic hepatic 
diseases. Marked cross-reactivity was only observed 
with serum specimens from patients with E.  multi- 
loculuris and E. uogefi infections [14]. Our results 
confirm that this antigen of E.  grunulosus with a 
molecular mass of 8 kDa is a highly specific diagnostic 
antigen also in patients with a malignancy displaying a 
cross-reaction with the hydatid fluid antigen. 
When non-specific bands of other molecular size 
were included, four of the 17 tumor patients studied 
had a single band reactivity (13-kDa band and 27-kDa 
band, respectively). Reactions of variable intensity in 
the 14-40-kDa region appear in sera of patients with 
other parasitic diseases such as schistosomiasis, fascio- 
liasis, or filariasis [14]. Moreover, the same study 
reported band reactivities in the 14-40-kDa region in 
one of 13 patients with an alcoholic cirrhosis 1141. It 
may be significant that a single band reactivity as 
exhibited by the above mentioned tumor patients was 
never observed with any hydatid patient. Independent 
of the preoperative or late postoperative treatment 
stages [15], hydatid patients regularly exhibited 
complex banding patterns unless they were completely 
seronegative [ 151. Consequently, the single band 
reactivity most likely reflected a tumor-induced cross- 
reactivity rather than a potential past exposure to the 
parasite. 
The distribution of the different malignancies did 
not differ significantly in patients with a positive EgHF 
reaction as compared with tumor patients in general 
(data not shown). On the other hand, tumor patients 
with a positive EgHF reaction had extensive tumor 
disease less frequently compared with limited neoplasm 
or disease in remission versus seronegative patients (24% 
versus 55%, y<0.05). Neoplasms modulate patients’ 
immune responses [16]. In early stages they stimulate 
the host immune system, whereas advanced, consum- 
ing malignancies may change the nutritional state 
of patients and lead to a suppression of immune 
responsiveness [16]. However, there is little experience 
with immunodiagnostics for echinococcosis in im- 
munosuppressed patients. One study reports on 17 
adult alveolar echinococcosis patients with immuno- 
suppression related to orthotopic liver transplantation 
[17]. The titer of specific antibodies decreased during 
the first 3 months in all patients but one. In four of 
nine patients with liver transplantation, the complete 
disappearance of specific antibodies occurred within 2 
years. In the remaining five patients, specific antibodies 
remained detectable. Suppression of both lympho- 
proliferative and humoral responses is well known in 
children infected with HIV [l8], and we found a report 
of a histologically confirmed alveolar echinococcosis of 
the liver in a 6-year-old girl with acquired immuno- 
deficiency syndrome demonstrating negative serologic 
tests for echinococcosis (ELISA with Em2 antigen, 
11/3-10 antigen and Em crude antigen, as well as 
ELISA with EgHF antigen) [19]. 
Although no statistical difference could be found 
in treatment procedures between both patient groups, 
the interindividual variability in intensity, timing and 
combination of radiotherapy, hormonal therapy, chemo- 
therapy and/or surgery may modulate the immune 
function in cancer patients in different ways [16]. 
Therefore, we studied the time course in an EgHF 
ELISA-seropositive, 65-year-old patient with a naso- 
pharyngeal neoplasm. The four ELISA follow-up 
investigations at  different time intervals revealed a 
significant decrease in the EgHF ELISA antibody 
concentration after reduction of the tumor size by 
chemo- and radiotherapy, and no subsequent rise in the 
antibody concentration. The antibody concentration 
remained constant and close to the threshold level, even 
after 18 months. 
In conclusion, the widely used screening EgHF 
ELISA test has a relatively low specificity and exhibits 
relatively frequently false-positive results in tumor 
patients. The Western blot test for E. grunulosus 
infections proved to be a highly specific immuno- 
diagnostic tool and enables discrimination between 
malignancy and hydatid disease. 
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